Rubhu Biologics

Rubhu Biologics is a private, early-revenue stage contract research organization providing specialized R&D services to accelerate the development of cell therapies and biologics. The company leverages a multidisciplinary team with expertise in immunology, cell biology, and molecular biology to offer services ranging from assay development and validation to preclinical immunological studies. Operating from a single facility in Georgia, it positions itself as a flexible, quality-driven partner for biotech firms, particularly those in oncology, autoimmune diseases, and diabetes. Its business model is entirely service-based, catering to the growing outsourced needs of the cell therapy sector.

Integrated service platform for biologics and cell therapy development, encompassing cell characterization, potency assays, immunological studies (immunogenicity/immunotoxicity), and mechanism of action studies. Expertise applied to T cells, NK cells, stem cells (MSC, iPSC), and islet cells.

Rubhu operates in the fragmented but competitive contract research market. It competes with large, full-service CROs (e.g., LabCorp, Charles River) that have dedicated cell therapy units, as well as smaller niche players like Cellero, Lonza's Vybion, and numerous regional labs. Differentiation is based on deep cell therapy expertise, personalized service, and flexibility, but scale and brand recognition are challenges against larger players.